These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33196697)

  • 1. Heterogeneity of CEACAM5 in breast cancer.
    Bechmann MB; Brydholm AV; Codony VL; Kim J; Villadsen R
    Oncotarget; 2020 Oct; 11(43):3886-3899. PubMed ID: 33196697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.
    Blumenthal RD; Leon E; Hansen HJ; Goldenberg DM
    BMC Cancer; 2007 Jan; 7():2. PubMed ID: 17201906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis.
    Powell E; Shao J; Picon HM; Bristow C; Ge Z; Peoples M; Robinson F; Jeter-Jones SL; Schlosberg C; Grzeskowiak CL; Yang F; Wu Y; Wistuba I; Moulder SL; Symmans WF; Scott KL; Edwards JR; Liang H; Heffernan TP; Piwnica-Worms H
    NPJ Breast Cancer; 2018; 4():9. PubMed ID: 29736411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEACAM5 has different expression patterns in gastric non-neoplastic and neoplastic lesions and cytoplasmic staining is a marker for evaluation of tumor progression in gastric adenocarcinoma.
    Liu JN; Wang HB; Zhou CC; Hu SY
    Pathol Res Pract; 2014 Oct; 210(10):686-93. PubMed ID: 25042385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
    Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
    Popovska S; Ivanov I
    Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer.
    Azari F; Kennedy GT; Chang A; Bernstein E; Nadeem B; Pèlegrin A; Cailler F; Sullivan NT; Kucharczuk J; Singhal S
    Ann Thorac Surg; 2023 Sep; 116(3):631-641. PubMed ID: 35644263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis.
    Li Q; Li Y; Li J; Ma Y; Dai W; Mo S; Xu Y; Li X; Cai S
    Int J Biol Sci; 2018; 14(7):726-735. PubMed ID: 29910683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
    Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
    J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis.
    Sano M; Aoyagi K; Takahashi H; Kawamura T; Mabuchi T; Igaki H; Tachimori Y; Kato H; Ochiai A; Honda H; Nimura Y; Nagino M; Yoshida T; Sasaki H
    Int J Oncol; 2010 Feb; 36(2):321-30. PubMed ID: 20043065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).
    Blumenthal RD; Hansen HJ; Goldenberg DM
    Cancer Res; 2005 Oct; 65(19):8809-17. PubMed ID: 16204051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients.
    Rivadeneira DE; Simmons RM; Christos PJ; Hanna K; Daly JM; Osborne MP
    J Am Coll Surg; 2000 Jul; 191(1):1-6; discussion 6-8. PubMed ID: 10898177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin's colocalization with the adhesion molecule CEACAM5 in cytoplasm of carcinoma of tongue and its correlation with the invasion of that diease.
    Zhang F; Jin Liu X; Qu X; Sheng Hu Z; Yang YM; Ma L; Liu P; Shi P; Cai Wei F
    Cancer Cell Int; 2012 Jun; 12(1):33. PubMed ID: 22738781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.